Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Dec 1;180(6):2227–2237. doi: 10.1084/jem.180.6.2227

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

PMCID: PMC2191798  PMID: 7525850

Abstract

An immunodominant epitope of myelin basic protein (MBP), VHFFKNIVTPRTP (p87-99), is a major target of T cells in lesions of multiple sclerosis (MS) and in experimental allergic encephalomyelitis (EAE). T cells found in EAE lesions bear the same amino acids in the third complementary determining region of the T cell receptor (TCR) as those found in MS lesions. We analyzed the trimolecular interactions between MBP p87-99, class II major histocompatibility complex (MHC), and TCR, and designed soluble inhibitors for therapy. F, N, I, and V at positions 90, 92, 93, and 94 interact with MHC, whereas K, T, and P at positions 91, 95, and 96 interact with TCR. The peptides, p87-99[95T > A] and p87-99[96P > A] could compete more effectively with p87-99 for binding to MHC and could antagonize the in vitro response to T cells to p87-99 more effectively than p87-99[91K > A]. However, only p87-99[91K > A] prevented and reversed EAE, indicating that the extent of MHC or TCR competition does not predict success in treating EAE. To elucidate the mechanism of inhibition of EAE, draining lymph node cells from rats immunized with the native peptide alone or together with each of the three TCR antagonists were challenged in vitro with p87-99. Administration of p87-99[91K > A], but not p87-99 [95T > A] or p87- 99[96P > A], reduced the production of tumor necrosis factor (TNF)- alpha and interferon (IFN) gamma. IFN-gamma and TNF-alpha are two cytokines that are critical in the pathogenesis of EAE and MS.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ben-Nun A., Wekerle H., Cohen I. R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol. 1981 Mar;11(3):195–199. doi: 10.1002/eji.1830110307. [DOI] [PubMed] [Google Scholar]
  2. Billiau A., Heremans H., Vandekerckhove F., Dijkmans R., Sobis H., Meulepas E., Carton H. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol. 1988 Mar 1;140(5):1506–1510. [PubMed] [Google Scholar]
  3. Campbell B., Vogel P. J., Fisher E., Lorenz R. Myelin basic protein administration in multiple sclerosis. Arch Neurol. 1973 Jul;29(1):10–15. doi: 10.1001/archneur.1973.00490250028003. [DOI] [PubMed] [Google Scholar]
  4. Chung I. Y., Norris J. G., Benveniste E. N. Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J Exp Med. 1991 Apr 1;173(4):801–811. doi: 10.1084/jem.173.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. De Magistris M. T., Alexander J., Coggeshall M., Altman A., Gaeta F. C., Grey H. M., Sette A. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 1992 Feb 21;68(4):625–634. doi: 10.1016/0092-8674(92)90139-4. [DOI] [PubMed] [Google Scholar]
  6. Duong T. T., St Louis J., Gilbert J. J., Finkelman F. D., Strejan G. H. Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J Neuroimmunol. 1992 Feb;36(2-3):105–115. doi: 10.1016/0165-5728(92)90042-j. [DOI] [PubMed] [Google Scholar]
  7. Evavold B. D., Allen P. M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991 May 31;252(5010):1308–1310. doi: 10.1126/science.1833816. [DOI] [PubMed] [Google Scholar]
  8. Evavold B. D., Sloan-Lancaster J., Hsu B. L., Allen P. M. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol. 1993 Apr 15;150(8 Pt 1):3131–3140. [PubMed] [Google Scholar]
  9. Fontana A., Fierz W., Wekerle H. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature. 1984 Jan 19;307(5948):273–276. doi: 10.1038/307273a0. [DOI] [PubMed] [Google Scholar]
  10. Franco A., Southwood S., Arrhenius T., Kuchroo V. K., Grey H. M., Sette A., Ishioka G. Y. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol. 1994 Apr;24(4):940–946. doi: 10.1002/eji.1830240424. [DOI] [PubMed] [Google Scholar]
  11. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C. G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science. 1992 Nov 27;258(5087):1491–1494. doi: 10.1126/science.1279812. [DOI] [PubMed] [Google Scholar]
  12. Gautam A. M., Lock C. B., Smilek D. E., Pearson C. I., Steinman L., McDevitt H. O. Minimum structural requirements for peptide presentation by major histocompatibility complex class II molecules: implications in induction of autoimmunity. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):767–771. doi: 10.1073/pnas.91.2.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gautam A. M., Pearson C. I., Sinha A. A., Smilek D. E., Steinman L., McDevitt H. O. Inhibition of experimental autoimmune encephalomyelitis by a nonimmunogenic non-self peptide that binds to I-Au. J Immunol. 1992 May 15;148(10):3049–3054. [PubMed] [Google Scholar]
  14. Gold D. P., Vainiene M., Celnik B., Wiley S., Gibbs C., Hashim G. A., Vandenbark A. A., Offner H. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. II. Biased T cell receptor V beta expression predominates in spinal cord infiltrating T cells. J Immunol. 1992 Mar 15;148(6):1712–1717. [PubMed] [Google Scholar]
  15. Harding C. V., Leyva-Cobian F., Unanue E. R. Mechanisms of antigen processing. Immunol Rev. 1988 Dec;106:77–92. doi: 10.1111/j.1600-065x.1988.tb00774.x. [DOI] [PubMed] [Google Scholar]
  16. Karin N., Szafer F., Mitchell D., Gold D. P., Steinman L. Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J Immunol. 1993 May 1;150(9):4116–4124. [PubMed] [Google Scholar]
  17. Kuroda Y., Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol. 1991 Nov;34(2-3):159–164. doi: 10.1016/0165-5728(91)90125-q. [DOI] [PubMed] [Google Scholar]
  18. Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E. O., McFarlin D. E., McFarland H. F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol. 1990 Jul 15;145(2):540–548. [PubMed] [Google Scholar]
  19. Martin R., Utz U., Coligan J. E., Richert J. R., Flerlage M., Robinson E., Stone R., Biddison W. E., McFarlin D. E., McFarland H. F. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol. 1992 Mar 1;148(5):1359–1366. [PubMed] [Google Scholar]
  20. Miller A., Lider O., Weiner H. L. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med. 1991 Oct 1;174(4):791–798. doi: 10.1084/jem.174.4.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mozes E., Dayan M., Zisman E., Brocke S., Licht A., Pecht I. Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells. EMBO J. 1989 Dec 20;8(13):4049–4052. doi: 10.1002/j.1460-2075.1989.tb08588.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mueller D. L., Jenkins M. K., Schwartz R. H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445–480. doi: 10.1146/annurev.iy.07.040189.002305. [DOI] [PubMed] [Google Scholar]
  23. Offner H., Hashim G. A., Celnik B., Galang A., Li X. B., Burns F. R., Shen N., Heber-Katz E., Vandenbark A. A. T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats. J Exp Med. 1989 Aug 1;170(2):355–367. doi: 10.1084/jem.170.2.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Offner H., Vainiene M., Gold D. P., Celnik B., Wang R., Hashim G. A., Vandenbark A. A. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. I. T cell receptor peptide regulation of T cell clones expressing cross-reactive V beta genes. J Immunol. 1992 Mar 15;148(6):1706–1711. [PubMed] [Google Scholar]
  25. Ostrov D., Krieger J., Sidney J., Sette A., Concannon P. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues. J Immunol. 1993 May 15;150(10):4277–4283. [PubMed] [Google Scholar]
  26. Ota K., Matsui M., Milford E. L., Mackin G. A., Weiner H. L., Hafler D. A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990 Jul 12;346(6280):183–187. doi: 10.1038/346183a0. [DOI] [PubMed] [Google Scholar]
  27. Panitch H. S., Hirsch R. L., Schindler J., Johnson K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987 Jul;37(7):1097–1102. doi: 10.1212/wnl.37.7.1097. [DOI] [PubMed] [Google Scholar]
  28. Powell M. B., Mitchell D., Lederman J., Buckmeier J., Zamvil S. S., Graham M., Ruddle N. H., Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol. 1990;2(6):539–544. doi: 10.1093/intimm/2.6.539. [DOI] [PubMed] [Google Scholar]
  29. Ruddle N. H., Bergman C. M., McGrath K. M., Lingenheld E. G., Grunnet M. L., Padula S. J., Clark R. B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med. 1990 Oct 1;172(4):1193–1200. doi: 10.1084/jem.172.4.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ruppert J., Alexander J., Snoke K., Coggeshall M., Herbert E., McKenzie D., Grey H. M., Sette A. Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2671–2675. doi: 10.1073/pnas.90.7.2671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sakai K., Zamvil S. S., Mitchell D. J., Hodgkinson S., Rothbard J. B., Steinman L. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9470–9474. doi: 10.1073/pnas.86.23.9470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Santambrogio L., Hochwald G. M., Saxena B., Leu C. H., Martz J. E., Carlino J. A., Ruddle N. H., Palladino M. A., Gold L. I., Thorbecke G. J. Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J Immunol. 1993 Jul 15;151(2):1116–1127. [PubMed] [Google Scholar]
  33. Selmaj K., Raine C. S., Cross A. H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol. 1991 Nov;30(5):694–700. doi: 10.1002/ana.410300510. [DOI] [PubMed] [Google Scholar]
  34. Seth A., Stern L. J., Ottenhoff T. H., Engel I., Owen M. J., Lamb J. R., Klausner R. D., Wiley D. C. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature. 1994 May 26;369(6478):324–327. doi: 10.1038/369324a0. [DOI] [PubMed] [Google Scholar]
  35. Sharief M. K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 1991 Aug 15;325(7):467–472. doi: 10.1056/NEJM199108153250704. [DOI] [PubMed] [Google Scholar]
  36. Sharma S. D., Nag B., Su X. M., Green D., Spack E., Clark B. R., Sriram S. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11465–11469. doi: 10.1073/pnas.88.24.11465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Smilek D. E., Wraith D. C., Hodgkinson S., Dwivedy S., Steinman L., McDevitt H. O. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9633–9637. doi: 10.1073/pnas.88.21.9633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sriram S., Steinman L. Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J Exp Med. 1983 Oct 1;158(4):1362–1367. doi: 10.1084/jem.158.4.1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Steinman L., Cohen I. R., Teitelbaum D., Arnon R. Regulation of autosensitisation to encephalitogenic myelin basic protein by macrophage-association and soluble antigen. Nature. 1977 Jan 13;265(5590):173–175. doi: 10.1038/265173a0. [DOI] [PubMed] [Google Scholar]
  40. Steinman L., Rosenbaum J. T., Sriram S., McDevitt H. O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7111–7114. doi: 10.1073/pnas.78.11.7111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Steinman L. Specific motifs in T cell receptor V beta D beta J beta gene sequences in multiple sclerosis lesions in brain. Behring Inst Mitt. 1994 Jul;(94):148–157. [PubMed] [Google Scholar]
  42. Steinman L. The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. Adv Immunol. 1991;49:357–379. doi: 10.1016/s0065-2776(08)60779-8. [DOI] [PubMed] [Google Scholar]
  43. Thornhill M. H., Wellicome S. M., Mahiouz D. L., Lanchbury J. S., Kyan-Aung U., Haskard D. O. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol. 1991 Jan 15;146(2):592–598. [PubMed] [Google Scholar]
  44. Voorthuis J. A., Uitdehaag B. M., De Groot C. J., Goede P. H., van der Meide P. H., Dijkstra C. D. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin Exp Immunol. 1990 Aug;81(2):183–188. doi: 10.1111/j.1365-2249.1990.tb03315.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wauben M. H., Boog C. J., van der Zee R., Joosten I., Schlief A., van Eden W. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J Exp Med. 1992 Sep 1;176(3):667–677. doi: 10.1084/jem.176.3.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wauben M. H., Joosten I., Schlief A., van der Zee R., Boog C. J., van Eden W. Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptide. J Immunol. 1994 Apr 15;152(8):4211–4220. [PubMed] [Google Scholar]
  47. Wilson D. B., Steinman L., Gold D. P. The V-region disease hypothesis: new evidence suggests it is probably wrong. Immunol Today. 1993 Aug;14(8):376–382. doi: 10.1016/0167-5699(93)90136-9. [DOI] [PubMed] [Google Scholar]
  48. Wraith D. C., McDevitt H. O., Steinman L., Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. Cell. 1989 Jun 2;57(5):709–715. doi: 10.1016/0092-8674(89)90786-1. [DOI] [PubMed] [Google Scholar]
  49. Wraith D. C., Smilek D. E., Mitchell D. J., Steinman L., McDevitt H. O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell. 1989 Oct 20;59(2):247–255. doi: 10.1016/0092-8674(89)90287-0. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES